Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa

NCT03248531 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT03248531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03248531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
UCB Biopharma SRL
Phase
Phase 2
Overall status
Completed
Start date
September 22, 2017
Completion date
February 21, 2019
Enrollment
90 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa